Vascular Biogenics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for cancer and immune/inflammatory indications. Co.'s main program in oncology is based on its proprietary Vascular Targeting System, platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Co.'s primary product candidate, VB-111 (ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, and which it has developed to programs for ovarian cancer, recurrent glioblastoma, an aggressive form of brain cancer, and thyroid cancer. The VBLT stock yearly return is shown above.
The yearly return on the VBLT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VBLT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|